Q-omics provides the consensus-scored MTRNR2L7 profile across patient tissues and cancer cell-line models. MTRNR2L7 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MTRNR2L7 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, MTRNR2L7 RNA expression shows 9,471 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, BRCA, and ACC as cancer lineages where MTRNR2L7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRNR2L7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRNR2L7 survival associations across molecular data types. MTRNR2L7 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRNR2L7 RNA expression–survival associations across cancer types. High MTRNR2L7 expression shows unfavorable associations in UCS, LUAD, CESC, STAD and COAD, but favorable associations in ACC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MTRNR2L7 RNA expression.
This table summarizes MTRNR2L7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTRNR2L7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRNR2L7 shows lower tumor expression in KIRC, COAD and KIRP and higher tumor expression in BRCA and LUAD. The BRCA box plot shows higher MTRNR2L7 RNA expression in tumor versus normal tissue (log2 FC = +0.041, t-test p = .005).
This table shows molecular features associated with MTRNR2L7 in patient tissues and cancer cell lines. In patient samples, MTRNR2L7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTRNR2L7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
